International Assets Investment Management LLC Increases Holdings in United Therapeutics Co. (NASDAQ:UTHR)

International Assets Investment Management LLC grew its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 13,769.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,015 shares of the biotechnology company’s stock after buying an additional 8,950 shares during the quarter. International Assets Investment Management LLC’s holdings in United Therapeutics were worth $1,982,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Atlas Capital Advisors LLC purchased a new stake in shares of United Therapeutics during the 4th quarter valued at about $51,000. Northwestern Mutual Wealth Management Co. raised its position in United Therapeutics by 49.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 65 shares during the period. Neo Ivy Capital Management purchased a new stake in United Therapeutics in the 2nd quarter worth about $48,000. Zions Bancorporation N.A. purchased a new stake in United Therapeutics in the 1st quarter worth about $66,000. Finally, Quantbot Technologies LP purchased a new stake in United Therapeutics in the 2nd quarter worth about $87,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $215.01, for a total value of $1,290,060.00. Following the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $7,869,150.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Nilda Mesa sold 325 shares of United Therapeutics stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total value of $77,285.00. Following the transaction, the director now directly owns 5,373 shares in the company, valued at approximately $1,277,699.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $215.01, for a total value of $1,290,060.00. Following the completion of the transaction, the executive vice president now owns 36,599 shares in the company, valued at $7,869,150.99. The disclosure for this sale can be found here. In the last three months, insiders have sold 129,790 shares of company stock worth $30,528,633. 12.50% of the stock is currently owned by company insiders.

United Therapeutics Price Performance

NASDAQ UTHR opened at $237.93 on Friday. The company has a market cap of $11.20 billion, a PE ratio of 11.99 and a beta of 0.52. The firm’s 50 day moving average price is $231.71 and its 200-day moving average price is $228.55. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41. United Therapeutics Co. has a 52-week low of $204.44 and a 52-week high of $261.54.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. During the same period last year, the business posted $2.67 EPS. The business’s revenue was up 25.1% compared to the same quarter last year. Sell-side analysts forecast that United Therapeutics Co. will post 23.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. SVB Leerink assumed coverage on shares of United Therapeutics in a research report on Monday, February 5th. They issued an “outperform” rating and a $330.00 price objective on the stock. The Goldman Sachs Group raised shares of United Therapeutics from a “sell” rating to a “neutral” rating and increased their price objective for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. Finally, HC Wainwright restated a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $292.67.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.